Bio-Rad Laboratories Inc. Class A

616.43+12.44+2.06%Vol 58.49K1Y Perf 51.62%
Apr 13th, 2021 14:57 DELAYED
BID615.83 ASK617.72
Open607.11 Previous Close603.99
Pre-Market- After-Market-
 - -%  - -
Target Price
678.33 
Analyst Rating
Strong Buy 1.00
Potential %
10.27 
Finscreener Ranking
★★★★★     64.84
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     67.37
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     80.18
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap18.40B 
Earnings Rating
Neutral
Price Range Ratio 52W %
75.22 
Earnings Date
5th May 2021

Today's Price Range

607.11621.00

52W Range

396.16689.00

5 Year PE Ratio Range

5.30288.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.61%
1 Month
7.66%
3 Months
-0.24%
6 Months
6.57%
1 Year
51.62%
3 Years
144.03%
5 Years
332.02%
10 Years
387.81%

TickerPriceChg.Chg.%
BIO616.4312.44002.06
AAPL134.343.10002.36
GOOG2 271.5316.74000.74
MSFT258.392.48000.97
XOM55.630.13000.23
WFC39.85-0.9200-2.26
JNJ159.27-2.3700-1.47
FB311.950.41000.13
GE13.46-0.1300-0.96
JPM154.73-1.2200-0.78
Financial StrengthValueIndustryS&P 500US Markets
2.20
3.40
0.02
0.02
225.50
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
56.50
193.60
199.10
52.70
84.36
RevenueValueIndustryS&P 500US Markets
1.97B
79.69
4.41
4.54
Earnings HistoryEstimateReportedSurprise %
Q04 20203.104.0129.35
Q03 20201.853.0062.16
Q02 20201.301.6123.85
Q01 20201.401.9136.43
Q04 20192.462.32-5.69
Q03 20191.361.6118.38
Q02 20191.391.5712.95
Q01 20191.121.6547.32
Earnings Per EndEstimateRevision %Trend
3/2021 QR2.50-4.94Negative
6/2021 QR2.21-19.93Negative
12/2021 FY11.2510.29Positive
12/2022 FY12.009.09Positive
Next Report Date5th May 2021
Estimated EPS Next Report2.50
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume58.49K
Shares Outstanding29.84M
Trades Count5.70K
Dollar Volume141.94M
Avg. Volume213.12K
Avg. Weekly Volume99.04K
Avg. Monthly Volume144.18K
Avg. Quarterly Volume209.67K

Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 603.99 per share at the end of the most recent trading day (a 0.05% change compared to the prior day closing price) with a volume of 90.04K shares and market capitalization of 18.40B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class A stock is 51.62%, while year-to-date (YTD) performance is 3.42%. BIO stock has a five-year performance of 332.02%. Its 52-week range is between 396.16 and 689, which gives BIO stock a 52-week price range ratio of 75.22%

Bio-Rad Laboratories Inc. Class A currently has a PE ratio of 4.70, a price-to-book (PB) ratio of 1.79, a price-to-sale (PS) ratio of 7.58, a price to cashflow ratio of 31.00, a PEG ratio of 2.32, a ROA of 35.09%, a ROC of 46.36% and a ROE of 47.15%. The company’s profit margin is 84.36%, its EBITDA margin is 199.10%, and its revenue ttm is $1.97 Billion , which makes it $79.68 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.50 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1), with a target price of $678.33, which is +10.27% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 9.08, ATR14 : 21.74, CCI20 : 191.14, Chaikin Money Flow : 0.04, MACD : -9.33, Money Flow Index : 54.46, ROC : 7.97, RSI : 39.39, STOCH (14,3) : 96.14, STOCH RSI : 0.45, UO : 59.32, Williams %R : -3.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Andrew J. Last (Option Excercise at a value of $0), Annette Tumolo (Option Excercise at a value of $191 184), Annette Tumolo (Sold 1 200 shares of value $768 865 ), Dara Wright (Option Excercise at a value of $0), Giovanni Magni (Option Excercise at a value of $2 579 316), Giovanni Magni (Sold 15 229 shares of value $7 914 650 ), Michael Crowley (Option Excercise at a value of $0), Michael Crowley (Sold 1 874 shares of value $945 271 ), Norman Schwartz (Option Excercise at a value of $6 258 180), Ronald W. Hutton (Option Excercise at a value of $0), Ronald W. Hutton (Sold 443 shares of value $202 606 ), Timothy S. Ernst (Option Excercise at a value of $63 728), Timothy S. Ernst (Sold 923 shares of value $591 501 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bio-Rad Laboratories Inc. Class A

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

67%33%

Bearish Bullish

59%41%

News

Stocktwits